Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 7/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636304 | 1.00 | ERN1 (0.42) | ERN1CYP3A4SLC40A1PTK2BSMN1; SMN2 | |
| SCHEMBL2192658 | 1.00 | ERN1 (0.42) | ERN1CYP3A4SLC40A1PTK2BSMN1; SMN2 | |
| SCHEMBL2193244 | 0.85 | SLC40A1 (0.46) | ERN1SLC40A1BRAFNR1I2 | |
| SCHEMBL2193238 | 0.85 | SLC40A1 (0.46) | ERN1SLC40A1BRAFNR1I2 | |
| SCHEMBL18636518 | 0.85 | SLC40A1 (0.46) | ERN1SLC40A1BRAFNR1I2 | |
| SCHEMBL2193968 | 0.82 | LMNA (0.44) | PTK2BSMN1; SMN2BRAFPIK3C3 | |
| SCHEMBL2193965 | 0.82 | LMNA (0.44) | PTK2BSMN1; SMN2BRAFPIK3C3 | |
| SCHEMBL3883018 | 0.75 | GPR35 (0.37) | — | |
| SCHEMBL3883014 | 0.75 | GPR35 (0.37) | — | |
| SCHEMBL1127359 | 0.74 | CYP3A4 (0.49) | ERN1CYP3A4SLC40A1PTK2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8642759-B2 | Benzene sulfonamide thiazole and oxazole compounds | GLAXOSMITHKLINE LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-8415345-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo SmithKline LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | ERN1 3675/4885CYP3A4 25/4885SLC40A1 3787/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | ERN1 3675/4885CYP3A4 25/4885SLC40A1 3787/4885 |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | ERN1 3675/4885CYP3A4 25/4885SLC40A1 3787/4885 |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | ERN1 3675/4885CYP3A4 25/4885SLC40A1 3787/4885 |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | ERN1 3675/4885CYP3A4 25/4885SLC40A1 3787/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | ERN1 3675/4885CYP3A4 25/4885SLC40A1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.